z-logo
open-access-imgOpen Access
Therapeutic potential of bleomycin plus suicide or interferon-β gene transfer combination for spontaneous feline and canine melanoma
Author(s) -
Lucrecia Agnetti,
Chiara Fondello,
Marcela Solange Villaverde,
Gerardo C. Glikin,
Liliana M.E. Finocchiaro
Publication year - 2017
Publication title -
oncoscience
Language(s) - English
Resource type - Journals
ISSN - 2331-4737
DOI - 10.18632/oncoscience.387
Subject(s) - bleomycin , suicide gene , interferon , apoptosis , cytotoxicity , melanoma , cancer research , genetic enhancement , biology , cell culture , programmed cell death , gene , in vivo , immunology , pathology , medicine , in vitro , chemotherapy , genetics
We originated and characterized melanoma cell lines derived from tumors of two feline and two canine veterinary patients. These lines reestablished the morphology, physiology and cell heterogeneity of their respective parental tumors. We evaluated the cytotoxicity of bleomycin (BLM) alone, or combined with interferon-β (IFN-β) or HSVtk/GCV suicide gene (SG) lipofection on these cells. Although the four animals presented stage III disease (WHO system), SG treated feline tumors displayed stable disease in vivo, while the canine ones exhibited partial response. Their derived cell lines reflected this behavior. Feline were significantly more sensitive than canine cells to IFN-β gene transfer. BLM improved the antitumor effects of both genes. The higher levels of reactive oxygen species (ROS) significantly correlated with membrane and DNA damages, emphasizing ROS intervention in apoptotic and necrotic cell death. After 3 days of BLM alone or combined with gene treatments, the colony forming capacity of two canine and one feline treatments survivor cells almost disappeared. Taken together, these results suggest that the treatments eradicated tumor initiating cells and support the clinical potential of the tested combinations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom